Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Micafungin Sodium

FDA-approved product (injectable, intravenous), marketed as Micafungin, Micafungin In Sodium Chloride 0.9%, Micafungin Sodium and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Micafungin Sodium
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antimycotics for systemic use
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AX05

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA66.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Micafungin Sodium in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Micafungin Sodium with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study Comparing Short-course Antifungal Therapy (SCAT) 7 Day vs Standard 14 Day Antifungal Therapy for Uncomplicated Candidemia

    NCT06907992 · start 2025-05-01

    Registered record
    Registry ID
    NCT06907992
    Conditions
    Candidemia
    Interventions
    Antifungal treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-05-01
    Completion
    2027-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidemia
    InterventionAntifungal treatment
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Antimicrobial Revision in Persistent Febrile Neutropenia

    NCT05784844 · start 2024-08

    Registered record
    Registry ID
    NCT05784844
    Conditions
    Febrile Neutropenia
    Interventions
    Meropenem; Micafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2024-08
    Completion
    2025-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionMeropenem; Micafungin
    PhasePhase 4
    Registry statusWithdrawn

  • Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection

    NCT06413056 · start 2022-10-20

    Registered record
    Registry ID
    NCT06413056
    Conditions
    Neonatal Infection; Invasive Fungal Infections
    Interventions
    Micafungin; Amphotericin B
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-10-20
    Completion
    2023-08-30
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeonatal Infection; Invasive Fungal Infections
    InterventionMicafungin; Amphotericin B
    PhasePhase 4
    Registry statusCompleted

  • To Evaluate the Efficacy and Safety of Micafungin in Preventing Invasive Mycosis After Liver Transplantation

    NCT04728971 · start 2022-10-01

    Registered record
    Registry ID
    NCT04728971
    Conditions
    Liver Transplantation
    Interventions
    Micafungin Sodium 50 MG Injection; Caspofungin Acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2022-10-01
    Completion
    2026-02-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Transplantation
    InterventionMicafungin Sodium 50 MG Injection; Caspofungin Acetate
    PhasePhase 4
    Registry statusUnknown

  • A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

    NCT05178862 · start 2022-08-03

    Registered record
    Registry ID
    NCT05178862
    Conditions
    Candidiasis, Invasive; Candidemia
    Interventions
    SCY-078; Fluconazole; Echinocandin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2022-08-03
    Completion
    2025-12-16
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Invasive; Candidemia
    InterventionSCY-078; Fluconazole; Echinocandin
    PhasePhase 3
    Registry statusTerminated

  • Evaluate Bioequivalence of Micafungin (50mg/Vial)

    NCT05496725 · start 2022-01-06

    Registered record
    Registry ID
    NCT05496725
    Conditions
    Invasive Candidiasis
    Interventions
    Micafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-01-06
    Completion
    2022-07-28
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Candidiasis
    InterventionMicafungin
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Micafungin for Injection in Prevention and Treatment of Fungal Infection in Hematological Tumors

    NCT04738955 · start 2021-02-01

    Registered record
    Registry ID
    NCT04738955
    Conditions
    Hematological Tumors Patients With High Risk Factors of Invasive Fungal Disease
    Interventions
    Micafungin Sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-02-01
    Completion
    2023-10-01
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematological Tumors Patients With High Risk Factors of Invasive Fungal Disease
    InterventionMicafungin Sodium
    PhasePhase 4
    Registry statusUnknown

  • Microbiome Alterations in IL10RA-deficient Patients After HSCT

    NCT03752372 · start 2017-10-01

    Registered record
    Registry ID
    NCT03752372
    Conditions
    Inflammatory Bowel Diseases; Microbiota
    Interventions
    hematopoietic stem cell transplantation
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2017-10-01
    Completion
    2020-02-28
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInflammatory Bowel Diseases; Microbiota
    Interventionhematopoietic stem cell transplantation
    PhaseNot recorded
    Registry statusTerminated

  • Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis (EPI Study)

    NCT02805049 · start 2017-01-28

    Registered record
    Registry ID
    NCT02805049
    Conditions
    Septic Shock; Peritonitis
    Interventions
    Echinocandins
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01-28
    Completion
    2018-06-18
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock; Peritonitis
    InterventionEchinocandins
    PhasePhase 4
    Registry statusCompleted

  • Micafungin Pharmacokinetics in Obese Patients

    NCT03102658 · start 2017-01

    Registered record
    Registry ID
    NCT03102658
    Conditions
    Morbid Obesity
    Interventions
    Micafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01
    Completion
    2017-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMorbid Obesity
    InterventionMicafungin
    PhasePhase 4
    Registry statusCompleted

  • Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis

    NCT03421002 · start 2015-05-30

    Registered record
    Registry ID
    NCT03421002
    Conditions
    Candidiasis, Systemic; Candida Meningitis
    Interventions
    Micafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-05-30
    Completion
    2018-04-10
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis, Systemic; Candida Meningitis
    InterventionMicafungin
    PhasePhase 2
    Registry statusCompleted

  • PEACE: Pediatric Antifungal Comparative Effectiveness

    NCT01869829 · start 2015-01

    Registered record
    Registry ID
    NCT01869829
    Conditions
    Pediatric Invasive Candidiasis
    Interventions
    Observational antifungal therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-01
    Completion
    2018-04
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatric Invasive Candidiasis
    InterventionObservational antifungal therapy
    PhaseNot recorded
    Registry statusCompleted

  • Fluconazole Versus Micafungin in Neonates With Candidiasis

    NCT02145832 · start 2014-10

    Registered record
    Registry ID
    NCT02145832
    Conditions
    Candidiasis
    Interventions
    Fluconazole; Micafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-10
    Completion
    2015-11
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCandidiasis
    InterventionFluconazole; Micafungin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease

    NCT02172768 · start 2014-10

    Registered record
    Registry ID
    NCT02172768
    Conditions
    Acute Graft Versus Host Disease Grade II-IV; Allogeneic Stem Cell Transplant; Acute Myeloid Leucaemia; Myelo Dysplastic Syndrome
    Interventions
    alternate dosing; daily dosing; micafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Graft Versus Host Disease Grade II-IV; Allogeneic Stem Cell Transplant; Acute Myeloid Leucaemia; Myelo Dysplastic Syndrome
    Interventionalternate dosing; daily dosing; micafungin
    PhasePhase 2
    Registry statusCompleted

  • Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

    NCT02244606 · start 2014-09

    Registered record
    Registry ID
    NCT02244606
    Conditions
    Mycoses; Candidiasis, Invasive; Candidemia
    Interventions
    SCY-078; Fluconazole; Micafungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09
    Completion
    2016-08
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycoses; Candidiasis, Invasive; Candidemia
    InterventionSCY-078; Fluconazole; Micafungin
    PhasePhase 2
    Registry statusCompleted